Standout Papers
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024)
- Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (2024)
Immediate Impact
1 by Nobel laureates 10 from Science/Nature 55 standout
Citing Papers
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Works of Gargi Patel being referenced
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Gargi Patel | 460 | 309 | 275 | 38 | 915 | |
| Yale Jiang | 112 | 435 | 420 | 36 | 1.0k | |
| Thomas Bradley | 173 | 98 | 278 | 53 | 941 | |
| Joseph Albanese | 122 | 128 | 340 | 44 | 833 | |
| Simon J. Hollingsworth | 343 | 146 | 340 | 54 | 923 | |
| Alessandra Felici | 475 | 351 | 291 | 49 | 1.1k | |
| Robert Mechera | 442 | 130 | 419 | 43 | 1.2k | |
| Lawrence Feldman | 372 | 374 | 214 | 81 | 893 | |
| A.C. Begg | 214 | 216 | 178 | 28 | 745 | |
| David Macfarlane | 337 | 179 | 111 | 32 | 944 | |
| Lingyun Xu | 252 | 112 | 276 | 40 | 835 |
All Works
Login with ORCID to disown or claim papers
Loading papers...